Advanced Enzyme Technologies Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Mukund Kabra

Chief executive officer

₹24.3m

Total compensation

CEO salary percentage	25.1%
CEO tenure	24.7yrs
CEO ownership	1.6%
Management average tenure	no data
Board average tenure	5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mukund Kabra's remuneration changed compared to Advanced Enzyme Technologies's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹1b
Sep 30 2023	n/a	n/a	₹1b
Jun 30 2023	n/a	n/a	₹1b
Mar 31 2023	₹24m	₹6m	₹1b
Dec 31 2022	n/a	n/a	₹979m
Sep 30 2022	n/a	n/a	₹960m
Jun 30 2022	n/a	n/a	₹995m
Mar 31 2022	₹22m	₹6m	₹1b
Dec 31 2021	n/a	n/a	₹1b
Sep 30 2021	n/a	n/a	₹1b
Jun 30 2021	n/a	n/a	₹1b
Mar 31 2021	₹21m	₹5m	₹1b
Dec 31 2020	n/a	n/a	₹1b
Sep 30 2020	n/a	n/a	₹1b
Jun 30 2020	n/a	n/a	₹1b
Mar 31 2020	₹19m	₹5m	₹1b
Dec 31 2019	n/a	n/a	₹1b
Sep 30 2019	n/a	n/a	₹1b
Jun 30 2019	n/a	n/a	₹1b
Mar 31 2019	₹17m	₹4m	₹1b
Dec 31 2018	n/a	n/a	₹1b
Sep 30 2018	n/a	n/a	₹1b
Jun 30 2018	n/a	n/a	₹1b
Mar 31 2018	₹15m	₹4m	₹901m

Compensation vs Market: Mukund's total compensation ($USD290.89K) is about average for companies of similar size in the Indian market ($USD267.24K).

Compensation vs Earnings: Mukund's compensation has been consistent with company performance over the past year.

CEO

Mukund Kabra (51 yo)

24.7yrs

Tenure

₹24,250,932

Compensation

Mr. Mukund Madhusudan Kabra serves as a Whole Time Director at Advanced Enzyme Technologies Ltd. since April 1, 2009 and also served as its Director since September 4, 1999. Mr. Kabra began at the junior-m...

Board Members

Name	Position	Tenure	Compensation	Ownership
Mukund Kabra	Whole Time Director	24.7yrs	₹24.25m	1.63% ₹ 720.0m
Nitin Deshmukh	Independent Director	1.8yrs	₹380.00k	no data
Sunny Sharma	Non-Executive Director	4.5yrs	₹330.00k	no data
Pramod Kasat	Independent Non-Executive Director	7.4yrs	₹1.26m	0.0045% ₹ 2.0m
Vasant Rathi	Chairman	31.2yrs	₹990.00k	38.68% ₹ 17.1b
Rasika Rathi	Additional Non-Executive Director	5.3yrs	₹580.00k	2.38% ₹ 1.1b
Vinodkumar Jajoo	Independent Director	5.3yrs	₹940.00k	no data
Rajshree Patel	Independent Director	3.9yrs	₹730.00k	no data
Vandana Tilak	Independent Director	less than a year	no data	no data

5.3yrs

Average Tenure

54yo

Average Age

Experienced Board: 540025's board of directors are considered experienced (5.3 years average tenure).

Advanced Enzyme Technologies Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Chairman recently bought ₹142m worth of stock

Chairman recently bought ₹2.7m worth of stock

Advanced Enzyme Technologies Limited Announces Board Changes

Insider recently sold ₹100m worth of stock

Advanced Enzyme Technologies Limited Announces Appointment of Mr. Nitin Jagannath Deshmukh as an Independent Director of the Company

Recent updates

Advanced Enzyme Technologies Limited (NSEI:ADVENZYMES) acquired additional 5.89% stake in Jc Biotech Private Limited for INR 56.1 million

Third quarter 2024 earnings released: EPS: ₹3.74 (vs ₹2.63 in 3Q 2023)

Advanced Enzyme Technologies Limited to Report Q3, 2024 Results on Feb 10, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Advanced Enzyme Technologies Limited to Report Q2, 2024 Results on Nov 07, 2023

First quarter 2024 earnings released: EPS: ₹2.58 (vs ₹1.60 in 1Q 2023)

Advanced Enzyme Technologies Declares Final Dividend for the Financial Year Ended March 31, 2023

Advanced Enzyme Technologies Limited to Report Q1, 2024 Results on Aug 12, 2023

Upcoming dividend of ₹1.00 per share at 1.2% yield

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Advanced Enzyme Technologies Limited Proposes Dividend Payable on or After August 16, 2023

Insufficient new directors

Chairman recently bought ₹142m worth of stock

Chairman recently bought ₹2.7m worth of stock

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Advanced Enzyme Technologies Limited Announces Board Changes

Advanced Enzyme Technologies Limited to Report Q4, 2023 Results on May 13, 2023

Third quarter 2023 earnings released: EPS: ₹2.63 (vs ₹2.46 in 3Q 2022)

Advanced Enzyme Technologies Limited to Report Q3, 2023 Results on Feb 11, 2023

Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 4.83% stake in JC Biotech Private Limited.

Price target decreased to ₹265

Advanced Enzyme Technologies Limited to Report Q2, 2023 Results on Nov 11, 2022

Insider recently sold ₹100m worth of stock

Advanced Enzyme Technologies Limited Announces Appointment of Mr. Nitin Jagannath Deshmukh as an Independent Director of the Company

Upcoming dividend of ₹1.00 per share

Advanced Enzyme Technologies Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Advanced Enzyme Technologies Limited, Annual General Meeting, Aug 19, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Advanced Enzyme Technologies Limited Recommends Dividend for the Financial Year Ended March 31, 2022

Advanced Enzyme Technologies Limited to Report Q4, 2022 Results on May 20, 2022

Price target increased to ₹380

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS misses analyst expectations

Advanced Enzyme Technologies Limited Announces Demise of Vilas Aurangabadkar, Independent Director

Insider recently sold ₹611k worth of stock

Second quarter 2022 earnings released: EPS ₹2.66 (vs ₹3.33 in 2Q 2021)

Advanced Enzymes Announces Positive Clinical Breakthrough in the Randomized Controlled Trials of Systemic Enzymes and Probiotics to Resolve Long Covid' Fatigue Symptoms

Upcoming dividend of ₹0.90 per share

Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 15% minority stake in JC Biotech Private Limited.

First quarter 2022 earnings released: EPS ₹3.40 (vs ₹3.07 in 1Q 2021)

Full year 2021 earnings released: EPS ₹13.09 (vs ₹11.58 in FY 2020)

Advanced Enzyme Technologies Limited Recommends Dividend for the Financial Year Ended March 31, 2021

Investor sentiment improved over the past week

Insider recently sold ₹5.7m worth of stock

Third quarter 2021 earnings released: EPS ₹3.86 (vs ₹3.01 in 3Q 2020)

Investor sentiment improved over the past week

New 90-day high: ₹364

Advanced Enzyme Technologies Limited to Report Q3, 2021 Results on Feb 12, 2021

Insider recently sold ₹674k worth of stock

Insider recently sold ₹695k worth of stock

Insider recently sold ₹716k worth of stock

Insider recently sold ₹6.7m worth of stock

Second quarter 2021 earnings released: EPS ₹3.33

Advanced Enzyme Technologies Limited to Report Q2, 2021 Results on Nov 12, 2020

Insider recently sold ₹606k worth of stock

Nalanda India Equity Fund Limited managed by Nalanda Capital Pte Ltd acquired 3.75% stake in Advanced Enzyme Technologies Limited (BSE:540025) from Advanced Vital Enzymes Pvt Ltd.

New 90-day high: ₹246

Insider recently sold ₹956.2k worth of stock

New 90-day high - ₹240

Earnings released

Advanced Enzyme Technologies Limited to Report Q1, 2021 Results on Aug 12, 2020

New 90-day high - ₹182

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members